NDA 208171 · Pharmacosmos
Monoferric
Ferric Derisomaltose · Intravenous
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jan 16, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
39
16 Phase 3, 18 recruiting
FAERS reports
1,366
726 serious, 51 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 29, 2026.
Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: who have intolerance to oral iron or have had unsatisfactory response to oral iron, or who have non-hemodialysis-dependent chronic kidney disease (NDD-CKD) MONOFERRIC is an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients: who have intolerance to oral iron or have had unsatisfactory response to oral iron. ( 1 ) who have non-hemodialysis-dependent chronic kidney disease. ( 1 )
Mechanism: Ferric derisomaltose is a complex of iron (III) hydroxide and derisomaltose, an iron carbohydrate oligosaccharide that releases iron. Iron binds to transferrin for transport to erythroid precursor cells to be incorporated into hemoglobin.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 23, 2026 Supplement 6 · Efficacy LetterLabel
- Jan 16, 2020 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
3 products under this application
- MONOFERRIC · FERRIC DERISOMALTOSE 1GM/10ML (100MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- MONOFERRIC · FERRIC DERISOMALTOSE 100MG/ML (100MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
- MONOFERRIC · FERRIC DERISOMALTOSE 500MG/5ML (100MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Ferric Derisomaltose" as an intervention, any sponsor and status, largest first.
- Reducing Anemia in Pregnancy in India: the RAPIDIRON TrialPivotal-lookingCompleted
Thomas Jefferson UniversityAcademic, hospital or other
NCT05358509 · 4,368 participants · Start Mar 15, 2021 · Primary completion Dec 14, 2023
Drug: Ferric carboxymaltose; Iron isomaltoside and 1 more · For: Iron Deficiency Anemia; Infant, Low Birth Weight; Anemia of Pregnancy
Sites: Bagalkot, India; Belagavi, India; Rāichūr, India · 4 sites in all
- Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart FailurePivotal-lookingRecruiting
Pharmacosmos A/SIndustry
NCT06929806 · 1,900 participants (planned) · Start May 1, 2025 · Primary completion Dec 1, 2027
Drug: Ferric Derisomaltose · For: Chronic Heart Failure; Iron Deficiencies
Sites: Pasadena, California
- Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney DiseasePivotal-lookingCompleted
Pharmacosmos A/SIndustry
NCT02940860 · 1,538 participants · Start Nov 29, 2016 · Primary completion May 29, 2018
Drug: Iron isomaltoside/ferric derisomaltose; Iron sucrose · For: Iron Deficiency Anaemia; Iron Deficiency Anemia; Chronic Kidney Disease
Sites: Huntsville, Alabama; Little Rock, Arkansas; Chula Vista, California · 141 sites in all
- Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)Pivotal-lookingCompleted
Pharmacosmos A/SIndustry
NCT02940886 · 1,512 participants · Start Nov 8, 2016 · Primary completion Mar 28, 2018
Drug: Iron isomaltoside/ferric derisomaltose; Iron sucrose · For: Iron Deficiency Anaemia; Iron Deficiency Anemia
Sites: Birmingham, Alabama; Dothan, Alabama; Guntersville, Alabama · 114 sites in all
- Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency: IRONMANPivotal-lookingCompleted
University of GlasgowAcademic, hospital or other
NCT02642562 · 1,160 participants (planned) · Start Aug 2016 · Primary completion Aug 26, 2022
Drug: Ferric Derisomaltose · For: Chronic Heart Failure; Iron Deficiency; Left Ventricular Systolic Dysfunction
Sites: Aberdeen, United Kingdom; Airdrie, United Kingdom; Antrim, United Kingdom · 72 sites in all
- IRONCARE: Iron Treatment in Older Patients With Hip FracturesPivotal-lookingNot yet recruiting
University of AarhusAcademic, hospital or other
NCT07659184 · 528 participants (planned) · Start Oct 1, 2026 · Primary completion Sep 30, 2028
Drug: Ferric Derisomaltose; Oral Iron (Ferrous sulphate) and 2 more · For: Hip Fracture; Anemia; Iron and 1 more
Sites: Aarhus N, Denmark; Herning, Denmark; Horsens, Denmark · 5 sites in all
- Accelerated Recovery for Total Knee Replacement Surgery With Preoperative Intravenous Iron Combined With Human Erythropoietin for Rapid Hematopoietic Mobilization to Prevent Postoperative AnemiaPivotal-lookingStatus unknown
West China HospitalAcademic, hospital or other
NCT05911438 · 419 participants (planned) · Start Jul 2023 · Primary completion Dec 2024
Drug: Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO) · For: Total Knee Arthroplasty
Sites: Chengdu, China
- High Dose IV Iron Plus ESA in Chemotherapy-induced AnemiaPivotal-lookingStatus unknown
Hallym University Medical CenterAcademic, hospital or other
NCT05768997 · 312 participants (planned) · Start Mar 1, 2023 · Primary completion Dec 31, 2025
Drug: Ferric Derisomaltose Injection; Darbepoetin Alfa Injection · For: Anemia
Sites: Anyang-si, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea288
- nausea162
- flushing157
- chest discomfort150
- back pain127
- infusion related reaction104
- dizziness100
- vomiting92
- pruritus90
- chest pain87
- abdominal pain74
- hypersensitivity69
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2020 | 6 |
| 2021 | 153 |
| 2022 | 189 |
| 2023 | 269 |
| 2024 | 272 |
| 2025 | 282 |
| 2026 | 194 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Monoferric (Ferric DerIsomaltose) · HCPCS J1437
2024 spending
$108M
Beneficiaries
41,968
54,664 claims
Per beneficiary
$2,572
2024 ASP limit $20.12 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $287,847 |
| 2021 | $13,124,539 |
| 2022 | $32,393,441 |
| 2023 | $69,618,170 |
| 2024 | $107,960,139 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Single-dose intravenous iron vs oral iron for treatment of maternal iron deficiency anemia: a randomized clinical trial.
Derman RJ, Bellad MB, Somannavar MS, et al. · Am J Obstet Gynecol 2025 · Randomized Controlled Trial, Multicenter Study
- A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose.
Kennedy NA, Achebe MM, Biggar P, et al. · Int J Clin Pharm 2023 · Systematic Review, Meta-Analysis
- Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
Kalra PR, Cleland JGF, Petrie MC, et al. · Lancet 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
Wolf M, Rubin J, Achebe M, et al. · JAMA 2020 · Comparative Study, Multicenter Study
- Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
Zoller H, Wolf M, Blumenstein I, et al. · Gut 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose.
Pollock RF, Kalra PA, Kalra PR, et al. · Adv Ther 2022 · Meta-Analysis, Systematic Review
Sponsor: Pharmacosmos
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.